Physician profile
Randy J Averback
NPI 1417995721
$5,802.85
in general payments reported to CMS, 2019-2025
33 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $225 · 2021: $903 · 2022: $1,717 · 2023: $700 · 2024: $732 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,043.53 | 2019-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $618.64 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $503.02 | 2019-2024 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $377.48 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $298.97 | 2019-2024 | |
| Amgen INC. | $283.70 | 2019-2024 | Repatha |
| Pfizer INC. | $263.98 | 2019-2025 | |
| Medtronic, INC. | $249.14 | 2021-2024 | Micra, Cobalt Dr Mri Surescan |
| Kowa Pharmaceuticals America, INC. | $242.42 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $215.67 | 2019-2022 | |
| Inari Medical, INC. | $190.45 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $153.38 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $150.17 | 2022-2024 | Verquvo |
| Abbott Laboratories | $116.86 | 2021 | |
| Edwards Lifesciences Corporation | $111.07 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.52 | 2019-2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $102.57 | 2019 | |
| Astellas Pharma US INC | $93.92 | 2019-2021 | |
| Novo Nordisk INC | $81.67 | 2022-2023 | Ozempic |
| Angiodynamics, INC. | $78.36 | 2024 | Alphavac |
| Gilead Sciences, INC. | $69.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.17 | 2022-2025 | |
| Scpharmaceuticals INC. | $65.60 | 2023-2024 | |
| Baxter Healthcare | $59.26 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Esperion Therapeutics, INC. | $56.60 | 2022-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $48.96 | 2024 | |
| Biotronik INC. | $28.88 | 2020 | |
| Sanofi-Aventis U.S. LLC | $23.80 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $23.80 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $23.28 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $22.33 | 2023 | Optimizer |
| Amarin Pharma, INC. | $20.29 | 2019 | |
| Medtronic Vascular, INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Averback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.